BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Toilet rats? Washington health officials warn of possible rodents in sewer systems after floods - 2Farmers call for French blockades over cow disease cull
- 3Manual for Tracking down Spending plan Agreeable Travel Objections
- 4Figure out How to Really focus on Your Dental Inserts for Durable Outcomes
- 55 Arising Professions in Environmentally friendly power
- Voting begins in Uganda’s presidential election during internet shutdown and polling station delays
- 3D Printers for Specialists
- Uzbekistan launches €9.46 billion green energy push, covering nation’s power needs
- The Forgotten BMW Coupe That Turned a 5 Series Into Something Far More Exotic
- The Latest: Fueling begins as NASA aims to send 1st crew to the moon in 53 years
- Poland Crypto Bill Clears Sejm Again, Defying President — Will “Restrictive” Rules Stick?
- Energy agency chief warns of 'black April' for oil supplies
- Archaeologists uncover details about the Hjortspring boat's origins
- A top Marine shares his secrets to keeping fit at 50
